

Additional Primary Doses (aka 3rd dose)

Date Updated: February 11th, 2022



Patients who meet the following criteria qualify for an “additional primary dose”.
Dose intervals and age of approval for additional primary doses vary by COVID-19 vaccine product.

Moderately to Severely Immunocompromising Conditions:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant
 - Within 2 years of transplantation or taking immunosuppression therapy
- Moderate or severe primary immunodeficiency
 - e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome
- Advanced or untreated HIV infection
 - People with HIV and CD4 cell counts $<200/\text{mm}^3$, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV

Moderately to Severely Immunocompromising Treatments:

- High-dose corticosteroids
 - $\geq 20\text{mg}$ prednisone or equivalent per day when administered for ≥ 2 weeks
- Alkylating agents
- Antimetabolites
- Transplant-related immunosuppressive drugs
- Cancer chemotherapeutic agents classified as severely immunosuppressive
- TNF blockers
- Other biologics that are immunosuppressive or immunomodulatory